Author: Barnaby Page
The common sense of CBD science, and why it doesn’t always come to the fore
Written by Barnaby Page || 21st April 2022 || Blog , Business briefing |
Is the current system of peer-reviewed journal publication the best way to get the best science on CBD and cannabis? There could be another way ...
Unfounded claims on cancer and COVID attract warning letters from US FDA
Written by Barnaby Page || 23rd December 2020 || Regulatory briefing |
Claims that CBD could help shrink tumours were among those censured by the US Food and Drug Administration (FDA) in its latest round of warning letters to the industry ...
So this is Brexit – but what does it mean for CBD trade, now or later?
Written by Barnaby Page || 3rd February 2020 || Regulatory briefing |
As the UK exits Europe and enters its 11-month period of transition, what does Brexit actually mean for cross-Channel relationships, and for the CBD industry in particular? ...
Boris’s Brexit: what it could mean for the UK CBD industry
Written by Barnaby Page || 16th December 2019 || Business briefing |
Boris Johnson’s landslide victory in the British general election means Brexit will almost certainly take place early in 2020. But will the strenthening of the Conservative grip on power have any direct impact on CBD? ...
FDA cracks down again on health claims, but seems receptive to CBD
Written by Barnaby Page || 26th November 2019 || Regulatory briefing |
Scrutiny of the CBD market appears to be growing at the US Food and Drug Administration (FDA), which this week reprimanded a further 15 companies for selling CBD products as drugs and also updated its advice to consumers...
CBD-based epilepsy drug Epidyolex gets the green light from Europe
Written by Barnaby Page || 23rd September 2019 || Regulatory briefing |
Epidyolex, the CBD-based medicine used to treat rare forms of epilepsy, has been approved by the European Medicines Agency (EMA) ...
Car drivers, stressed execs are among latest targets for CBD firms
Written by Barnaby Page || 1st April 2019 || Business briefing |
CBD-infused auto fuel and an inhalable “cannabidiol homologue” are among the latest products launched by companies from outside the CBD sector keen to leverage its paradigm...
Berkeley team hold out hope for cannabinoids synthesised from yeast
Written by Barnaby Page || 14th March 2019 || Business briefing |
Obscure cannabinoids and even completely new ones could be produced synthetically from yeast, along with THC and CBD, according to scientists at the University of California in Berkeley ...
Science review sees promise and problems in medical use of CBD
Written by Barnaby Page || 19th February 2019 || Business briefing |
CBD shows promise for treating some medical conditions but the potential for interactions with other drugs is a cause for concern, as is poor quality control, according to a recent review of science in the field ...
WHO recommends removing CBD from world narcotics schedules
Written by Barnaby Page || 18th February 2019 || Regulatory briefing |
CBD is likely to be removed from the scope of the most significant international treaty on drug control, following a favourable report by the World Health Organization (WHO), which also recommends downgrading cannabis ...
Where in the world are the countries most likely to legalise cannabis?
Written by Barnaby Page || 17th January 2019 || Regulatory briefing |
Researchers in Portugal have developed an algorithm to identify characteristics that suggest the nations most likely to legalise recreational cannabis ... We still regulate foods and health claims, FDA reminds US CBD industry
Written by Barnaby Page || 23rd December 2018 || Regulatory briefing |
Removing hemp from the federal narcotics Schedule 1 list does not mean that all CBD products are now permitted, the US Food and Drug Administration (FDA) has warned ...
Austria confirms ban on use of CBD in cosmetics
Written by Barnaby Page || 23rd December 2018 || Regulatory briefing |
The use of any cannabis extract in cosmetics is forbidden in Austria, authorities have recently confirmed ...
CBD could hinder potential of cannabis to treat glaucoma, study warns
Written by Barnaby Page || 20th December 2018 || Business briefing |
The presence of CBD could render cannabis useless as a treatment for glaucoma, new research warns. Long-term use of the substance may even worsen one of the main risk factors for the eye disease ...
Equilibrium to add CBD to recovery shots; new CBD beer hits shelves
Written by Barnaby Page || 30th November 2018 || Business briefing |
British detox products supplier Equilibrium Labs is to add CBD to its Sober Up shots next year, in a move that could benefit those with foggy heads thanks to a new CBD beer also hitting shelves. A CBD-infused version...
CBD treatments on the way as FDA grants 20th ‘orphan drug’ designation
Written by Barnaby Page || 14th November 2018 || Business briefing |
The number of cannabidiol-based pharmaceutical products in the pipeline continues to grow, with the US Food and Drug Administration (FDA) recently granting yet another orphan drug designation for CBD ...
All CBD products for animals will be treated in the UK as medicine
Written by Barnaby Page || 14th November 2018 || Regulatory briefing |
The UK’s Veterinary Medicines Directorate (VMD) has told CBD-Intel that even a product not normally considered a medicine, such as a pet food or livestock feed, will be treated as a pharmaceutical if it contains CBD ...
Don’t judge cannabis by THC/CBD content alone, say scientists
Written by Barnaby Page || 1st November 2018 || Business briefing |
Many cannabis strains marketed as distinct are in fact chemically much the same, but there may also be non-obvious differences and their effects on humans should not be judged purely on THC and CBD content, scientists say ...
Day One for Canada – the first step into a brave new world
Written by Barnaby Page || 17th October 2018 || Business briefing |
Canada’s cannabis age has officially dawned, with some CBD products as well as the plant itself becoming legal for retail and personal possession ...
CBD medicines for animals will need UK government approval
Written by Barnaby Page || 26th September 2018 || Regulatory briefing |
CBD-based medical treatments for animals will need government approval before being sold in the UK, after the country’s Veterinary Medicines Directorate (VMD) decided they fall under the definition of veterinary medicines ...
Canadians plant the seeds of industry growth across Europe
Written by Barnaby Page || 13th September 2018 || Business briefing |
Companies from Canada’s large cannabis sector are continuing to invest in central and eastern Europe ...
Plan to create micro-organisms that will make cannabinoids in lab
Written by Barnaby Page || 12th September 2018 || Business briefing |
Rare cannabinoids that cannot practically be extracted from hemp will instead be manufactured by specially-created micro-organisms in a partnership between a Canadian and a US company ...
Epilepsy research charity warns against unlicensed CBD products
Written by Barnaby Page || 12th September 2018 || Business briefing |
A British health charity has warned people with epilepsy against using CBD products that do not have a pharmaceutical licence ...